MTOR and sarcoma: Exposure of sarcoma cells to neratinib, [pazopanib + entinostat], or the three-drug combination enhanced YAP and TAZ phosphorylation in parallel to a profound inactivation of mTOR resulting in phosphorylation of gate-keeper protein ATG13 S318.